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ORIGINAL ARTICLE
Introduction: Pathologic examination of mediastinal lymph nodes 
(MLNs) after resection of non–small-cell lung cancer is critical in 
the determination of prognosis and postoperative management. 
Although systematic nodal dissection is recommended, the quality of 
pathologic lymph-node staging often falls short of recommendations 
in practice. We tested the feasibility of improving pathologic lymph-
node staging of resectable non–small-cell lung cancer by using a pre-
labeled specimen-collection kit.
Methods: Case-control study with comparison of 51 resections, using 
a special lymph-node collection kit, with 51 controls matched for 
surgeon, extent of resection, pathologist, and T category. Appropriate 
statistical methods were used for all comparisons.
Results: The median number of MLNs examined increased from one 
in the control group, to six in the case group (p < 0.001). The per-
centage of resections attaining the National Comprehensive Cancer 
Network-recommended quality of MLN examination, and the pro-
portion that would have been eligible for recent landmark postre-
section adjuvant therapy trials increased significantly (p < 0.001). 
The duration of surgery and postoperative complication rates were 
similar between cases and controls. Eighteen percent of kit cases had 
positive MLN, compared with 8% of controls.
Conclusions: The use of a specialized specimen-collection kit for 
MLN examination was feasible, markedly improved MLN staging, 
and showed a trend toward increased detection of patients with MLN 
metastasis, with only a modest increase in duration of surgery, and no 
increase in perioperative morbidity, mortality, or hospital length of stay.
Key Words: Staging, Non–small-cell lung cancer, Mediastinal 
lymph nodes, Quality improvement, Surgical resection.
(J Thorac Oncol. 2012;7: 1276–1282)
Surgical resection is the primary curative treatment modal-ity for non–small-cell lung cancer (NSCLC). In the United 
States, 29% of all patients diagnosed with NSCLC undergo 
curative-intent surgical resection, an annual case volume of 
about 60,000 resections.1,2 Although the vast majority of long-
term survivors undergo surgery, only 73% of patients with 
stage IA, 58% with IB, 46% with IIA, 36% with IIB, and 
22% with IIIA NSCLC survive to 5 years.3 Nodal metasta-
sis sequentially diminishes postresection 5-year survival rates 
from 56% in patients with N0 disease to 38% in those with 
N1, 22% with N2, and 6%with N3.4 The N-category is thus a 
powerful determinant of survival in resectable NSCLC.
Careful examination of the surgical-resection specimen 
for lymph-node metastases is important for prognostication 
and selection of postoperative adjuvant therapy.5–8 Accurate 
collection and analysis of lymph nodes during pulmonary 
resection is imperative to provide patients with high-quality 
care. Examination of most N1 lymph nodes, located within 
the resected lung, can be regarded as primarily the responsi-
bility of the pathologist. Examination of hilar and mediastinal 
lymph nodes (MLN), however, depends on the collaborative 
efforts of the surgeon and pathologist. The relevant lymph 
nodes must be collected consistently, and labeled using stan-
dard nomenclature before they can be examined effectively.
There is consensus on the need for examination of lymph 
nodes from certain stations, including hilar and subcarinal 
stations in all patients, the lower right paratracheal nodes in 
those with right-side tumors, and the subaortic and para-aortic 
nodes in those with left-side tumors.9,10 Random examination 
that fails to encompass these minimum stations and, worse, no 
examination of MLNs, is associated with significantly worse 
survival, probably because of understaging.11–13
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Our detailed investigation of MLN-examination prac-
tices after lung resection in the Memphis Metropolitan Area 
revealed quality deficits in the current practice: 59% of cases 
did not have hilar nodes, 42% had no MLNs, and 90% had 
fewer than three MLN stations.14 Furthermore, 92% of the 
resections failed to achieve minimum recommended MLN-
examination standards in an audit of pathology reports, and 
70% of surgical operation notes described a suboptimal MLN-
examination procedure in a blinded audit by an independent 
surgeon.15
In response to these findings, we designed a special 
surgical lymph-node specimen-collection kit to improve the 
intraoperative collection of lymph nodes during lung resection 
surgery. Our aim was to improve the accuracy and quality of 
MLN staging during surgical resection for lung cancer.
MATERIALS AND METHODS
We conducted a case-control study with the approval of 
the Institutional Review Board of the University of Tennessee 
(project approval number 10-01026-XP), which waived the 
informed consent requirement for this quality-improvement 
study. All operations were performed by board-certified car-
diothoracic surgeons. We obtained all lymph-node– examina-
tion information from the final pathology report and abstracted 
clinical data, including information about patients’ intra- and 
postoperative experience from operating-room logs and other 
clinical records. Patients who had received preoperative che-
motherapy or radiation therapy were ineligible. Data on the kit 
cases were collected prospectively.
Specimen-Collection Kit
We designed a self-contained kit with specimen-col-
lection cups prelabeled with the standard anatomic name and 
number of each of the following 12 lymph-node stations: 
right upper paratracheal (2R), left upper paratracheal (2L), 
prevascular (3a), retrotracheal (3p), lower right paratracheal 
(4R), lower left paratracheal (4L), subaortic (5), para-aortic 
or phrenic (6), subcarinal (7), paraesophageal (8), pulmonary 
ligament (9), and hilar (10). One set of kits was labeled for use 
in right, another set for left, lung resections. In the right-side 
kits, specimen cups for stations 2R, 4R, 7, 8, 9, and 10R were 
conspicuously marked as mandatory for sampling, whereas 
stations 4L, 5, 6, 7, 8, 9, and 10L were marked as mandatory 
in the left-side kits. We used the International Association for 
the Study of Lung Cancer lymph-node map for lymph-node 
station nomenclature.4
Controls
We designed a set of controls to enable us account for 
potentially confounding factors during our study. We created 
a historical control cohort using a predetermined hierarchi-
cal set of matching criteria in the following priority order: 
surgeon, extent of resection, pathologist, and American Joint 
Committee on Cancer T category. When multiple matches 
were available, we selected the control closest in time to the 
case. We selected the historical controls from the Memphis 
Metropolitan Area Quality of Surgical Resection database of 
lung resection cases from 2004 to 2009.14
We recruited six surgeons to participate in the study. All 
other surgeons who operated at the study institution were iden-
tified as nonparticipating surgeons. To adjust for confound-
ing unrelated system-wide practice changes during the study 
period, we also compared lung cancer resections performed by 
participating surgeons within the year immediately preceding 
kit deployment with cases performed by the same surgeons 
using the kit. In addition, we monitored resections performed 
by nonparticipating surgeons before and after deployment of 
the kit in the study institution. Finally, we evaluated resec-
tions performed by participating surgeons after the onset of 
kit deployment but which, although eligible, were performed 
without the kit because of inadvertent logistic failure of kit 
requisition. The data on all control operations performed after 
the time of study onset were collected prospectively.
Statistical Analysis
We used descriptive analysis to compare patient char-
acteristics, lymph-node examination characteristics, and 
perioperative complications between cases and controls. 
Unadjusted statistical significance was assessed using 
McNemar’s matched χ2 test for categorical variables, and 
matched t test for continuous variables. Because our study 
matched cases with controls in a hierarchical order by sur-
geon, extent of resection, pathologist, and T category, we used 
matched Poisson regression for count variables (e.g., num-
ber of lymph nodes examined and number of lymph nodes 
with metastasis), and matched logistic regression for binary 
variables (e.g., yes/no status of MLN examined, lymph nodes 
with metastasis, and surgery complications), and matched 
linear regression for continuous variables. Age, race, sex, and 
insurance status were also included in the multivariate model. 
For unmatched analysis, we used the Pearson χ2 test, t test, 
and Poisson regression. We used Stata 12 × t module for sta-
tistical analysis.
RESULTS
From November 8, 2010 to October 11, 2011, 51 patients 
underwent surgical resection with intraoperative collection of 
their MLN specimen with the lymph-node collection kit (kit 
cases). We matched these cases with 51 historical controls. 
The demographic, clinical, and tumor-resection characteris-
tics of the cases and controls were very similar (Table 1). All 
patients had resection with negative margins.
Number and Distribution of Examined Lymph 
Nodes 
Significantly more hilar, mediastinal, and total lymph 
nodes were examined in the kit cases (Table 2). All kit cases 
had at least one MLN examined, whereas 49% of the controls 
had no MLN examined, including 6% with neither N1 nor N2 
lymph nodes. The improvement in lymph-node examination 
was largely because of an increase in the number of stations 
from which MLN were collected, from one in the controls to 
four stations in the cases.
The majority of the cases achieved sampling of lymph 
nodes from stations 7, 8, and 9, whereas these stations were 
examined in less than 25% of the controls. Station 10 was 
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examined in 43% of controls, compared with 76% of cases 
(p = 0.009). In right-side cases, examination of stations 
2R and 4R increased significantly (p = 0.008 and <0.001, 
respectively); in left-side cases, examination of stations 
5 and 6 also improved (p = 0.02 and 0.06, respectively). 
Examination of lymph nodes from stations not tagged as 
mandatory remained infrequent. For example, only 3 cases 
(6%) had sampling of lymph nodes from station 3, no controls 
had lymph nodes examined from this station, and no cases 
or controls had lymph nodes from contralateral mediastinal 
stations.
The Influence of Technique of Resection  
on Lymph-Node Examination 
Most patients had open thoracotomy, but 12% of kit cases 
and 10% of controls had video-assisted thoracoscopic surgery. 
Kit cases with open thoracotomy had a median of 6 MLN 
TABLE 1. Comparison of Key Characteristics Between Cases 
with Surgical Kits and Matched Controls
Variablea
Case Control
pN = 51 N = 51
Patient demographics
 Age, median (range) 67 (49–87) 64 (36–82) 0.06
 Male sex (%) 45 37 0.42
 Race (%) — — 0.40
  African American 37 29 —
  White 63 71 —
 Insurance status (%) — — 0.76
  Third party (± Medicare) 67 69 —
  Medicare 24 25 —
  No insurance 10 6 —
Disease characteristics
 Histology (%) — — 0.51
  Adenocarcinoma 61 71 —
  Squamous 25 22 —
  Other 14 8 —
 Differentiation (%) — — 0.51
  Well/moderate 49 45 —
  Poorly/undifferentiated 29 24 —
  Not reported 22 31 —
 Tumor size, median  
(interquartile range)
2.8 (2.0–4.5) 2.5 (1.7–3.2) 0.08
 T category (%) — — 0.83
  1 55 61 —
  2 35 31 —
  3/4 10 8 —
Preoperative staging evaluation (%)
 CT scan 100 100 —
 PET-CT scan 92 37 <0.001
 Preoperative mediastinoscopy 10 8 0.73
Resection characteristics (%)
 Extent
 Pneumonectomy 2 6 0.50
 Bilobectomy 12 8 —
 Lobectomy 86 86 —
 Margin negative status (%) 100 100 —
Technique (%)
 Open thoracotomy 88 90 0.75
 Video-assisted thoracic  
surgery (VATS)
12 10 —
CT, computed tomography; PET, positron emission tomography.
aAll variables reported as percentage of cohort, unless stated otherwise.
TABLE 2. Comparison of the Number of Lymph Nodes 
Examined
Case Control
pN = 51 N = 51
Number of lymph nodes examined
 All cases, median (IQR)
  From N1 stations 5 (3–7) 3 (1–6) 0.001
  From N2 stations 6 (4–9) 1 (0–3) <0.001
  From all stations 12 (9–15) 5 (2–8) <0.001
 From open cases
  N1 5 (4–7) 3 (1–6) 0.001
  N2 6 (4–9) 0 (0–2) <0.001
  All 13 (9–15) 5 (2–8) <0.001
 In VATS cases
  N1 5 (2–6) 4 (2–5) 0.66
  N2 5 (3–6) 3 (2–3) 0.33
  All 9 (7–10) 7 (6–8) 0.29
Number of N2 stations examined
 All cases
  Median 4 0 <0.001
  Interquartile range (IQR) 3–5 0–2 —
  Range 1–6 0–4 —
 Open thoracotomy cases,  
median (IQR)
4 (3–5) 0 (0–1) <0.001
 VATS cases, median (IQR) 4 (3–4) 2 (1–2) <0.001
Examination of mandatory stations (%)
 All cases
  7 78 22 0.001
  8 55 10 0.002
  9 75 20 <0.001
  10 76 43 0.009
 Right-sided cases only N = 34 N = 32 —
  2R 44 9 0.008
  4R 85 16 <0.001
 Left-sided cases only N = 17 N = 19 —
  5 82 21 0.02
  6 53 5 0.06
Proportion of patients without lymph nodes (%)
 From N1 stations 0 12 0.01
 From N2 stations 0 43 <0.001
 From anywhere 0 6 0.08
Detection of lymph node metastasis
 Number of lymph nodes with metastasis median (range)
  N1 stations 0 (0–1) 0 (0–10) 0.67
  Station 10 0 (0–4) 0 (0–10) 0.40
  N2 stations 0 (0–5) 0 (0–3) 0.26
  Total 0 (0–7) 0 (0–11) 0.19
 Number of N2 stations with 
metastasis
0 (0–2) 0 (0–3) 0.38
IQR, interquartile range; VATS, video-assisted thoracoscopic surgery.
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(interquartile range [IQR], 4–9), compared with 0 (0–2) nodes 
in controls (p < 0.001). A median of four MLN stations were 
examined in the kit cases with open thoracotomy compared 
with a median of zero stations in controls (p < 0.001). Although 
the number of lymph nodes examined in video-assisted 
thoracoscopic surgery resections was similar between cases and 
controls, the number of MLN stations from which lymph nodes 
were obtained increased from a median of two in controls, to 
four stations in kit cases (p < 0.001) (Table 2).
Impact of Specimen-Collection Kit on 
Participating Surgeons’ Lymph-Node Counts
To account for unrelated institutional changes in quality 
of surgical lymph-node staging, we compared the kit cases 
with several other controls. In 33 resections performed by 
participating surgeons in the 12 months immediately preceding 
study activation, a median of four (IQR, 2–7) N1, three (IQR 1–5) 
N2, seven (IQR 4–12) total lymph nodes were examined along 
with one (IQR 0–2) MLN station. These were all significantly 
less than the kit cases (p = 0.008 for the N1 comparison and 
p < 0.001 for all others). The number of lymph nodes and 
lymph-node stations examined were significantly higher in the 
kit cases than in the 14 cases performed by nonparticipating 
surgeons during the time of the study. The pattern and quality 
of lymph-node examination in nonparticipating surgeons’ cases 
did not improve during the time of our study.
Finally, there were eight cases performed by participating 
surgeons after the date of study commencement, which would 
have been eligible for use of the kit, but in which logistic glitches 
with kit deployment prevented use of the kit. The number of 
lymph nodes examined in these poststudy  activation nonkit cases 
by participating surgeons was significantly less than those in the 
kit cases (Table 3). Indeed, it was very similar to the resections 
performed in the year immediately preceding the study (Fig. 1).
Attainment of Recommended Quality Criteria
Fifty-seven percent of kit cases met the International 
Association for the Study of Lung Cancer criteria (Table 4) for 
complete resection, defined as the presence of all the follow-
ing: negative resection margin, examination of at least three 
lymph nodes each from N1 and N2 stations, examination of a 
minimum of six total lymph nodes, lymph nodes from at least 
TABLE 3. Comparison of Kit Cases to Various Controls to Account for Unrelated Secular 
Changes in Practice
Participating Surgeons
Before Kit  
(2009–2010) N = 33 After Kit N = 51 p
Number of lymph nodes, median (range; IQR)
 N1 4 (1–15; 2–7) 5 (1–13; 3–7) 0.008
 N2 3 (0–15; 1–5) 6 (2–19; 4–9) <0.001
 Total 7 (1–27; 4–12) 12 (4–30; 9–15) <0.001
 Number of N2 stations 1 (0–4; 0–2) 4 (1–6; 2–5) <0.001
Kit Cases vs. 
Concurrent 
Nonparticipating 
Surgeons’ Cases Kit Cases N = 51
Nonparticipating 
Surgeons Cases After Kit 
Deployment, N = 14 p
Number of lymph nodes, median (range; IQR)
 N1 5 (1–13; 3–7) 4 (0–18; 1–4) 0.001
 N2 6 (2–19; 4–9) 1 (0–14; 0–3) <0.001
 Total 12 (4–30; 9–15) 6 (1–18; 2–8) <0.001
 Number of N2 stations 4 (1–6; 2–5) 0 (0–4; 0–1) <0.001
Nonparticipating 
Surgeons
Before Kit Deployment 
Date N = 10
After Kit Deployment 
Date N = 14
p
Number of lymph nodes, median (range; IQR)
 N1 3 (2–7; 2–5) 4 (0–18; 1–4) 0.49
 N2 2 (0–9; 1–7) 1 (0–14; 0–3) 0.04
 Total 6 (2–14; 4–9) 6 (1–18; 2–8) 0.08
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three different N2 stations, at least one lymph node from sta-
tion 7 and negative “highest” MLN. Only 4% of the controls 
achieved this (p = 0.03). Majority of the controls were classi-
fied as indeterminate resections.
Achievement of good quality resection criteria was sig-
nificantly improved in the kit cases (p < 0.001). For example, 
the National Comprehensive Cancer Network recommendation 
for examination of lymph nodes from at least three mediastinal 
stations was met in 76% of kit cases, compared with 12% of con-
trols; 94% of kit cases would have met surgical-quality eligibility 
criteria for the RADIANT trial, whereas 73% of controls would 
have been disqualified by the requirement for examination of at 
least two MLN stations. Furthermore, although 20% of the kit 
cases met the American College of Surgeons Oncology Group 
definition of MLN dissection, no control patient attained this.
Detection of Lymph-Node Metastasis
There were few MLNs with metastasis detected 
(Table 5). The median number of MLNs with metastasis was 
zero in both cases and controls (95th percentile 2 versus 1, 
range, 0–5 versus 0–3, respectively). Nine kit cases (18%) had 
MLN metastasis, compared with four controls (8%).
Impact on Operative and Postoperative 
Complications 
Other than a median increase in operation time of 
27 minutes, there was no difference in intra- or postoperative 
experience or complication rates between the cases and 
 controls. Bleeding (as judged by estimated blood loss or use 
of blood transfusion), length of stay in the intensive care unit 
or hospital, duration of chest tube drainage, postoperative 
 cardiopulmonary complication rates, and 30-day mortality 
rates, were similar (Table 6).






RADIANT (>1 N2 lymph node 
stations)
94 27 <0.001
NCCN (>2 N2 lymph node stations) 76 12 <0.001
ECOG 63 8 <0.001
 Right: 4R + 7 74 13 <0.001
 Left: 5 + 6 + 7 41 0 0.002
ACOSOG
 Systematic sampling 26 0 <0.001
  Right: 2R + 4R + 7 + 10R 26 0 0.002
  Left: 5 + 6 + 7 + 10L 24 0 0.03
 Mediastinal lymph node dissection 20 0 <0.001
  Right: 2R + 4R + 7 + 8 + 9 + 10R 21 0 0.007
  Left: 5 + 6+ 7 + 8 + 9 + 10L 18 0 0.06
Resection statusa
 Complete 57 4 0.03
 Indeterminate 43 96 —
ACOSOG, American College of Surgeons Oncology Group; ECOG, Eastern 
Cooperative Oncology Group; NCCN, National Comprehensive Cancer Network; 
RADIANT, OSI Pharmaceuticals’ RADIANT study.
aAs defined by International Association for the Study of Lung Cancer9 and 
 European Society of Thoracic Surgeons,10 complete resection must meet all the 
 following criteria: negative resection margin, examination of at least three lymph nodes 
each from N1 and N2 stations, examination of a minimum of six total lymph nodes, 
lymph nodes from at least three different N2 stations, at least one lymph node from 
 station 7 and negative “highest” mediastinal lymph node. Indeterminate resection: 
 negative margins, with one or more of other criteria not met. 
TABLE 5. Comparison of Stage Distribution and Impact on 
Eligibility for Postoperative Adjuvant Therapy
Case Control p
Nodal stage distribution (%) 0.23
 N0 71 75 —
 N1 12 12 —
 N2 18 8 —
 Nx (not determined) 0 6 —
Overall stage distribution (%) 0.27
 I 65 69 —
 II 14 12 —
 III 22 14 —
Eligibility for postoperative adjuvant therapy (%)
 Chemotherapy 36 26 0.25
 Radiation 18 8 0.17
TABLE 6.  Operative and Postoperative Complication Rates 
and Duration of Hospital Admission
Clinical Experience Case Control p
Duration of surgery (minutes)
 Median 151 124 0.77
 Interquartile range 119–174 98–154 —
 Range 53–254 65–600 —
Estimated blood loss (cc)
 Median 200 200 0.98
 Interquartile range 100–400 100–300 —
 Range 0–1200 0–1500 —
Intraoperative blood transfusion units
 Median (range) 0 (0–2) 0 (0–3) 0.50
Duration of hospital admission (days)
 Median 8 7 0.90
 Interquartile range 5–10 6–10 —
 Range 2–39 2–35 —
Duration of chest tube drainage (days)
 Median 4 4 0.52
 Interquartile range 3–7 3–7 —
 Range 0–38 0–18 —
Duration of ICU admission 
(days)
0.77
 Median 3 3 —
 Interquartile range 2–4 2–5 —
 Range 0–26 1–15 —
Frequency of postoperative complications (%)
 Arrhythmia 22 16 0.64
 Myocardial infarction 2 2 0.57
 Pneumonia 10 8 0.85
 30-day mortality 2 4 —
ICU, intensive care unit.
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DISCUSSION
We demonstrate the feasibility of improving pathologic 
staging of lung cancer by means of a specifically designed 
lymph-node specimen-collection kit. The kit was readily 
adopted by the cardiothoracic surgery operating-room team. 
Improvements included elimination of nonexamination of 
MLNs, a general increase in the number of lymph nodes 
examined, increase in the number of stations from which a 
lymph-node specimen was obtained, and increase in likelihood 
of examination of lymph nodes from certain specific stations, 
which are widely agreed to be required for the accurate staging 
of resected lung cancer. The result of all this was a significant 
improvement in the quality of pathologic nodal staging.
This was achieved at the expense of a median 27-minute 
increase in the duration of the surgical procedure, but no 
increase in perioperative complication rates or duration 
of intensive care unit or hospital admission. The impact on 
stage distribution, which a feasibility study such as this is not 
powered to demonstrate, although not statistically significant, 
is interesting. The proportion of patients with N2 disease 
increased from 8% to 18%, and the proportion of patients 
who would have been identified as potential beneficiaries of 
postoperative adjuvant chemotherapy or radiation therapy, 
increased. Importantly, in this era of intense research into 
ways of improving adjuvant-therapy results, disqualification 
of patients from eligibility for contemporary postoperative 
adjuvant therapy trials, such as the recently completed 
RADIANT study16 or the ongoing Eastern Cooperative 
Oncology Group 1505 study,17 because of suboptimal MLN 
examination, would have been significantly reduced by use of 
this simple device (Table 4).
Use of the kit was associated with improvement in sur-
geon performance in the operating room, and improvement in 
the quality of the pathology examination. There appeared to 
be a causal relationship between use of the kit and improve-
ment in the quality of lymph-node examination. This observa-
tion is supported by the regression in quality of lymph-node 
examination in eligible cases performed without the kit by 
participating surgeons, to the level in the period immedi-
ately preceding introduction of the kit (Fig. 1). We attribute 
this phenomenon to the fact that the quality of lymph-node 
examination is influenced by the combination of surgeon fac-
tors, pathology practice, and less obvious factors such as the 
adequacy of specimen identification, and security of the chain 
of specimen handling between the operating room and the 
pathology laboratory.18 The kit is designed to rectify potential 
problems in each of these putative quality breakdown sites.
Correct anatomical mapping of the lymph nodes was 
done in all the kit cases. Prelabeling the kit improved the com-
munication between surgeon and pathologist, which is vital to 
a thorough and anatomically accurate final pathology report. 
However, a few problems remain. The pattern of lymph-node 
examination in the kit cases seems more similar to system-
atic sampling than a MLN dissection in most cases, and few 
cases included lymph nodes beyond the minimum mandated 
stations. However, the results of the American College of 
Surgeons Oncology Group Z0030 study, in which there was 
equivalent survival between patients randomized to systematic 
sampling or MLN dissection suggests that this issue should 
not cause much concern.19 Furthermore, the kit will accom-
modate the product of a more extensive dissection. Pathology 
errors persist. For example, in one case, the pathologist erro-
neously attributed a documented positive N2 lymph node 
as N1 (understaging error). However, such errors are easily 
recognized when pathologists use anatomic nomenclature to 
identify every lymph node’s station of origin.
Limitations of our study include the case-control design 
and relatively small sample size. We attempted to minimize 
the potential for bias by comparing our intervention cohort 
with several different controls. We compared each kit case 
with controls that we matched for key potentially confound-
ing factors including surgeon, extent of resection, pathologist, 
and T category. We also attempted to control for independent 
secular changes in practice by comparing kit cases with nonkit 
cases performed by participating surgeons in the 12 months 
immediately preceding deployment of the kit. Finally, we 
used nonparticipating surgeons’ cases as an external control 
to detect any unrelated system-wide improvement in lymph-
node staging practice. We found no improvement in the non-
participating surgeons’ cases during the time of our study. The 
key characteristics of the cases and controls were very similar, 
except for the identified rate of preoperative positron emis-
sion tomography (PET)/computed tomography (CT) staging. 
We were only able to verify the use of preoperative PET/CT 
in 37% of controls, compared with 92% of kit cases. This dis-
cordance may reflect evolution of practice, but may just as 
likely indicate our inability to identify all control patients who 
had a preoperative PET/CT scan outside the institution where 
their lung resection was done. It is important to point out that 
any true bias from this discrepancy (less thorough preopera-
tive staging in the control patients) would be expected to lead 
to a higher rate of detection of pathologic N2 disease in the 
control patients. This would tend to blunt the effect size of the 
improved surgical MLN staging associated with use of the kit. 
Our report may therefore be conservative.
The relevance of our findings to surgeons operating in 
high-volume centers of excellence can be debated. However, 
because most lung cancer surgery in the United States is per-
formed outside such institutions, our results are probably rel-
evant to the majority of lung cancer surgeons in the country.1 
Besides, pathologists in high-volume centers would probably 
appreciate the increased precision in specimen identification 
and labeling provided by the kit.
Obviously, the main rationale for improving hilar and 
MLN examination is to identify all patients with lymph-node 
metastasis. Although we doubled the detection of patients with 
N2 disease, this achievement was not statistically significant. 
Furthermore, we have provided no data on patient outcomes. 
Our study was not designed to achieve these aims. Rather, 
we aimed to estimate the effect size of this corrective inter-
vention, to estimate the sample size that would be required 
in a prospective randomized controlled trial that can examine 
these important questions. We are currently designing such a 
trial. However, the improvement in quality of surgical lymph-
node staging is incontrovertible. Routine use of this specimen-
collection kit can be justified as a quality improvement tool.
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